Literature DB >> 18198825

2-Oxotetrahydroquinoline-based antimalarials with high potency and metabolic stability.

Vivek J Bulbule1, Kasey Rivas, Christophe L M J Verlinde, Wesley C Van Voorhis, Michael H Gelb.   

Abstract

We report a series of novel inhibitors of protein farnesyltransferase based on the 2-oxotetrahydroquinoline scaffold. We developed an efficient synthesis of these compounds. These compounds show selective inhibtion of the malaria versus human farnesyltransferase and inhibit the growth of the malaria parasite in the low nanomolar range. Some of the compounds are at least an order of magnitude more stable to metabolic degradation than the corresponding tetrahydroquinolines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18198825     DOI: 10.1021/jm7013138

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

Review 1.  Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future.

Authors:  Wim G J Hol
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-04-16       Impact factor: 1.056

Review 2.  Repurposing strategies for tropical disease drug discovery.

Authors:  Dana M Klug; Michael H Gelb; Michael P Pollastri
Journal:  Bioorg Med Chem Lett       Date:  2016-03-30       Impact factor: 2.823

3.  Prenyltransferase Inhibitors: Treating Human Ailments from Cancer to Parasitic Infections.

Authors:  Joshua D Ochocki; Mark D Distefano
Journal:  Medchemcomm       Date:  2013-03       Impact factor: 3.597

4.  3,4-Bis[1-(prop-2-yn-yl)-1H-indol-3-yl]-1H-pyrrole-2,5-dione.

Authors:  Mu-Hua Huang; Yong-Chen Gao; Feng-Ling Yang; Yun-Jun Luo
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-05-18

5.  1-[(1-Methyl-1H-imidazol-5-yl)meth-yl]-1H-indole-5-carbonitrile.

Authors:  Josephus Jacobus de Jager; Vincent J Smith
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-11-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.